Legend Biotech (LEGN) news
Recent news
Logitech International - Reduces share capital to CHF 39.04 mln - SEC filing
Logitech International S.A. has announced a reduction in its share capital to CHF 39.04 million, as disclosed in a recent SEC filing. The move is part of the company’s ongoing corporate governance strategy and reflects adjustments to its capital structure. The filing, submitted under the Securities…
AInvest Wire · 1d agoLegend Biotech launches inaugural elite grant program to advance the next generation of CAR-T innovation in multiple myeloma
AInvest Wire · Oct 1, 2026Legn: Carvykti median PFS reaches 60.5 months in RRMM trial
Legend Biotech (NASDAQ: LEGN) has reported updated data from its ongoing clinical trial of CARVYKTI (ciltacabtagene autoleucel) in the treatment of relapsed or refractory multiple myeloma (RRMM). According to the latest findings, the median progression-free survival (PFS) for patients receiving…
AInvest Wire · Sep 25, 2026Legn: Carvkti keeps 50% of RRMM patients progression-free 5 yrs
Recent data from Legend Biotech and Johnson & Johnson indicate that Carvykti, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, has demonstrated durable efficacy in treating relapsed or refractory multiple myeloma (RRMM). According to the latest findings,…
AInvest Wire · Sep 25, 2026Legend Biotech shares down 1.8%; co appoints Ingrid Zhang as CEO
Legend Biotech (LEGN) shares declined 1.8% in early trading on September 15, 2026, following the announcement that new Chief Executive Officer . Zhang, a veteran biopharmaceutical industry leader with prior experience at Novartis, AstraZeneca, Pfizer, and McKinsey, succeeds interim CEO Alan Bash,…
AInvest Wire · Sep 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.